| Literature DB >> 30268562 |
George Cholankeril1, Andrew A Li2, Brittany B Dennis3, Alice E Toll4, Donghee Kim1, C Andrew Bonham5, Satheesh Nair6, Aijaz Ahmed7.
Abstract
The introduction of direct-acting antiviral (DAA) agents and the opioid epidemic have resulted in an increased interest in liver transplantation (LT) of organs from donors with hepatitis C virus (HCV)-related viremia.1 In March of 2015, the Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) implemented a policy to perform HCV nucleic acid testing (NAT) in all HCV-seropositive donors. An open-label, single-center experience with 10 patients using a multistep informed consent reported successful transplantation of HCV-seropositive viremic (HCV-V) kidneys into HCV-seronegative recipients.2 Subsequently, a case was reported in which an HCV-V liver was transplanted into a HCV-seronegative recipient.3 In collaboration with OPTN/UNOS, we identified cases in which HCV-V deceased donor livers were transplanted into HCV-seronegative recipients.Entities:
Year: 2018 PMID: 30268562 PMCID: PMC6470034 DOI: 10.1016/j.cgh.2018.09.036
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN: 1542-3565 Impact factor: 11.382